Verrica Pharmaceuticals Inc.
VRCA
$0.4891
$0.02264.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.66% | 187.45% | 61.61% | 3.18% | -43.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.66% | 187.45% | 61.61% | 3.18% | -43.27% |
| Cost of Revenue | -22.57% | 157.31% | 109.36% | 152.09% | 128.35% |
| Gross Profit | 37.32% | -146.36% | -176.75% | -446.62% | -526.92% |
| SG&A Expenses | 24.35% | 96.84% | 302.48% | 257.25% | 171.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.40% | 62.03% | 187.55% | 182.48% | 125.37% |
| Operating Income | -4.14% | -53.81% | -233.74% | -256.32% | -196.90% |
| Income Before Tax | -14.31% | -75.92% | -271.06% | -257.15% | -173.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.31% | -75.92% | -271.06% | -257.15% | -173.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.31% | -75.92% | -271.06% | -257.15% | -173.59% |
| EBIT | -4.14% | -53.81% | -233.74% | -256.32% | -196.90% |
| EBITDA | -3.52% | -53.59% | -237.85% | -261.46% | -200.72% |
| EPS Basic | -5.05% | -69.93% | -251.00% | -162.67% | -78.40% |
| Normalized Basic EPS | -9.06% | -64.85% | -265.08% | -168.90% | -79.55% |
| EPS Diluted | -5.05% | -69.57% | -249.50% | -161.77% | -77.90% |
| Normalized Diluted EPS | -9.06% | -64.85% | -265.08% | -168.90% | -79.55% |
| Average Basic Shares Outstanding | 14.22% | 5.68% | 8.82% | 21.62% | 32.90% |
| Average Diluted Shares Outstanding | 14.22% | 5.68% | 8.81% | 21.60% | 32.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |